Drug
Axatilimab clinical trials
Also written SNDX-6352 and INCA034176.
- studies test it
- 24
- open now
- 13
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the axatilimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2025 (7); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 16
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 13
Incyte Corporation (6) · Syndax Pharmaceuticals (4) · Northside Hospital, Inc. (2) · Stephen Shiao (2) · M.D. Anderson Cancer Center (2) · Incyte Biosciences Japan GK (1) · University of Utah (1) · Medical College of Wisconsin (1)
Often tested with
Tested in the same studies.
Ruxolitinib (2) · Pembrolizumab (2) · Retifanlimab (2) · Adrenal Cortex Hormones (1) · Nivolumab (1) · Decitabine (1) · Venetoclax (1) · Olaparib (1)
Studies
Open first, then newest update. How each study uses axatilimab is read from its arms, and is right about nine times in ten.
Testing it · 24
- Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AMLNot yet recruitingPhase 1Northside Hospital, Inc.NCT07511062Written as Axatilimab
- Axatilimab + CAR-T for High-Risk LymphomaNot yet recruitingPhase 1Northside Hospital, Inc.NCT07638982Written as Axatilimab
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseRecruitingPhase 3Incyte CorporationNCT06585774Written as INCA034176
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)RecruitingPhase 2Incyte CorporationNCT07124078Written as INCA034176
- Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07128381Written as Axatilimab (SNDX-6352)
- Axatilimab for Sclerotic Chronic Graft-versus-Host DiseaseRecruitingPhase 2Fred Hutchinson Cancer CenterNCT07011810Written as Axatilimab
- CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell TransplantationNot yet recruitingPhase 2Medical College of WisconsinNCT07808112Written as Axatilimab
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingPhase 1Dana-Farber Cancer InstituteNCT06488378Written as Axatilimab
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06320405Written as Axatilimab
- Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host DiseaseRecruitingPhase 2University of MiamiNCT06663722Written as Axatilimab
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)RecruitingPhase 2Syndax PharmaceuticalsNCT04710576Written as Axatilimab
- ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationNot yet recruitingPhase 2Stephen ShiaoNCT07015853Written as Axatilimab
- Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationRecruitingPhase 2Stephen ShiaoNCT05491226Written as Axatilimab
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseActive, not recruitingPhase 2Incyte CorporationNCT06388564Written as Axatilimab
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host DiseaseActive, not recruitingPhase 3Incyte Biosciences Japan GKNCT06263478Written as INCA034176
- A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)SuspendedPhase 1M.D. Anderson Cancer CenterNCT06959537Written as Axatilimab (SNDX-6352)
- Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS TrialWithdrawnPhase 2Mayo ClinicNCT07349771Written as Axatilimab
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic TherapyActive, not recruitingPhase 3Incyte CorporationNCT06821542Written as INCA034176
- A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHDActive, not recruitingPhase 1/2Incyte CorporationNCT06843408Written as INCA034176
- Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin LymphomaActive, not recruitingPhase 2University of UtahNCT05723055Written as Axatilimab
See all 24 studies that test axatilimab →
Given in every arm · 3 — axatilimab is usual care beside what is tested
- Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic LeukemiaRecruitingPhase 1/2Uma BorateNCT06523556Written as Axatilimab
- Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04301778Written as SNDX-6352
- A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid TumorsCompletedPhase 1Syndax PharmaceuticalsNCT03238027Written as Axatilimab
Codes
What other systems call axatilimab · ClinicalTrials.gg INT001459
- MeSH (NLM) C000711669axatilimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) R96Z451BMCAXATILIMABConfirmed FDA, NLM
- NCI Thesaurus C155813AxatilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711669 | axatilimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R96Z451BMC | AXATILIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C155813 | Axatilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.